ATPase family AAA domain containing 3A is an anti-apoptotic factor and a secretion regulator of PSA in prostate cancer

International Journal of Molecular Medicine

Volumn 28, Issue 1, 2011, Pages 9-15

  Huang, Kuo Hsuan ^a,b   Chow, Kuan Chih ^c   Chang, Hui Wen ^d   Lin, Tze Yi ^d   Lee, Meng Chih ^a,e  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

ATPase family AAA domain containing 3A; Disease progression; Drug resistance; Prostate cancer; Prostate specific antigen

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; ATPASE FAMILY AAA DOMAIN CONTAINING 3A PROTEIN; CISPLATIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CHINESE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADENOSINE TRIPHOSPHATASES; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MITOCHONDRIAL PROTEINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY;

EID: 79955863711     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.670     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 59: 225-249, 2009.
2. Annual reports of the Department of Health, Executive Yuan, Republic of China, 2009.
3. Simoneau AR: Treatment- and disease-related complications of prostate cancer. Rev Urol 8 (Suppl. 2): S56-S67, 2006.
4. Hsu NY, Ho HC, Chow KC, et al: Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res 61: 2727-2731, 2001.
5. Shen H, Kauvar L and Tew KD: Importance of glutathione and associated enzymes in drug response. Oncol Res 9: 295-302, 1997. (Pubitemid 127825983)
6. Huang KH, Chiou SH, Chow KC, et al: Overexpression of aldo-keto reductase 1C2 is associated with disease progression in patients with prostatic cancer. Histopathology 57: 384-394, 2010.
7. Chiang YY: Hepatocyte growth factor induces hypoxia-related interleukin-8 expression in lung adenocarcinoma cells. Mol Carcinog 48: 662-670, 2009.
8. Chen JT, Huang CY, Chiang YY, et al: HGF increases cisplatin resistance via down-regulation of AIF in lung cancer cells. Am J Respir Cell Mol Biol 38: 559-565, 2008.
9. Fang HY, Chang CL, Hsu SH, et al: The ATPase family, AAA domain containing 3A is a novel anti-apoptotic factor in lung adenocarcinoma cells. J Cell Sci 123: 1171-1180, 2010.
10. Gires O, Münz M, Schaffrik M, et al: Profile identification of disease-associated humoral antigens using AMIDA, a novel proteomics-based technology. Cell Mol Life Sci 61: 1198-1207, 2004. (Pubitemid 38703749)
11. Geuijen CA, Bijl N, Smit RC, et al: A proteomic approach to tumour target identification using phage display, affinity purification and mass spectrometry. Eur J Cancer 41: 178-187, 2005. (Pubitemid 40029671)
12. Ueda M, Hung YC, Chen JT, et al: Infection of human papillomavirus and overexpression of dihydrodiol dehydrogenase in uterine cervical cancer. Gynecol Oncol 102: 173-181, 2006. (Pubitemid 44041634)
13. Remmele W and Schicketanz KH: Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 189: 862-866, 1993.
14. Sävblom C, Malm J, Giwercman A, Nilsson JA, Berglund G and Lilja H: Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age. Prostate 65: 66-72, 2005. (Pubitemid 41318832)
15. Mucci LA, Powolny A, Giovannucci E, et al: Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 27: 5627-5633, 2009.
16. Spannuth WA, Sood AK and Coleman RL: Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 5: 194-204, 2008. (Pubitemid 351493679)
17. Igawa M, Urakami S, Shiina H, et al: Immunohistochemical evaluation of proliferating cell nuclear antigen, prostate-specific antigen and alpha 1-antichymotrypsin in human prostate cancer. Br J Urol 77: 107-112, 1996.
18. Stege RH, Tribukait B, Carlström KA, Grande M, Pousette AH, et al: Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy. Prostate 38: 183-188, 1999. (Pubitemid 29054934)
19. Mikolajczyk SD, Millar LS, Wang TJ, et al: A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 60: 756-759, 2000. (Pubitemid 30094578)
20. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC and Rosenfeld RG: Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75: 1046-1053, 1992.
21. Denmeade SR, Sokoll LJ, Dalrymple S, et al: Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 54: 249-257, 2003. (Pubitemid 36228161)
22. Niu Y, Yeh S, Miyamoto H, et al: Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res 68: 7110-7119, 2008.
23. Lilja H, Cockett AT and Abrahamsson PA: Prostate specific antigen predominantly forms a complex with alpha 1-antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum. Cancer 70: 230-234, 1992.
24. Lin TS, Chiou SH, Wang LS, et al: Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. Oncol Rep 12: 717-723, 2004.
25. Chen DR, Chu CY, Chen CY, et al: Expression of short form oncostatin M receptor as a decoy receptor in lung adenocarcinomas. J Pathol 215: 290-299, 2008. (Pubitemid 351956710)